JP2016528295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528295A5 JP2016528295A5 JP2016536456A JP2016536456A JP2016528295A5 JP 2016528295 A5 JP2016528295 A5 JP 2016528295A5 JP 2016536456 A JP2016536456 A JP 2016536456A JP 2016536456 A JP2016536456 A JP 2016536456A JP 2016528295 A5 JP2016528295 A5 JP 2016528295A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- fusion polypeptide
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 92
- 229920001184 polypeptide Polymers 0.000 claims description 91
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 91
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 76
- 230000004927 fusion Effects 0.000 claims description 49
- 150000001413 amino acids Chemical class 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 14
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 7
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 6
- 239000000710 homodimer Substances 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 4
- 230000002784 sclerotic effect Effects 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000001826 Marfan syndrome Diseases 0.000 claims description 2
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 102000007562 Serum Albumin Human genes 0.000 claims description 2
- 108010071390 Serum Albumin Proteins 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 201000008982 Thoracic Aortic Aneurysm Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010047141 Vasodilatation Diseases 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 208000007474 aortic aneurysm Diseases 0.000 claims description 2
- 230000036755 cellular response Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000009918 complex formation Effects 0.000 claims description 2
- 208000003457 familial thoracic 1 aortic aneurysm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 230000002008 hemorrhagic effect Effects 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 125000003473 lipid group Chemical group 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 11
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 2
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000012634 fragment Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 102000046181 human GDF15 Human genes 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868713P | 2013-08-22 | 2013-08-22 | |
| US61/868,713 | 2013-08-22 | ||
| US201361906270P | 2013-11-19 | 2013-11-19 | |
| US61/906,270 | 2013-11-19 | ||
| US201361906849P | 2013-11-20 | 2013-11-20 | |
| US61/906,849 | 2013-11-20 | ||
| PCT/US2014/052130 WO2015027082A1 (en) | 2013-08-22 | 2014-08-21 | Tgf-beta receptor type ii variants and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149750A Division JP2019194270A (ja) | 2013-08-22 | 2019-08-19 | Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016528295A JP2016528295A (ja) | 2016-09-15 |
| JP2016528295A5 true JP2016528295A5 (enExample) | 2017-09-28 |
Family
ID=52480573
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536456A Withdrawn JP2016528295A (ja) | 2013-08-22 | 2014-08-21 | Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用 |
| JP2019149750A Withdrawn JP2019194270A (ja) | 2013-08-22 | 2019-08-19 | Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用 |
| JP2021079785A Pending JP2021112212A (ja) | 2013-08-22 | 2021-05-10 | Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用 |
| JP2023199004A Pending JP2024015040A (ja) | 2013-08-22 | 2023-11-24 | Ｔｇｆ－ベータ受容体ｉｉ型変異体およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019149750A Withdrawn JP2019194270A (ja) | 2013-08-22 | 2019-08-19 | Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用 |
| JP2021079785A Pending JP2021112212A (ja) | 2013-08-22 | 2021-05-10 | Ｔｇｆ−ベータ受容体ｉｉ型変異体およびその使用 |
| JP2023199004A Pending JP2024015040A (ja) | 2013-08-22 | 2023-11-24 | Ｔｇｆ－ベータ受容体ｉｉ型変異体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US20150056199A1 (enExample) |
| EP (2) | EP3705498A1 (enExample) |
| JP (4) | JP2016528295A (enExample) |
| CN (2) | CN116655801A (enExample) |
| AU (2) | AU2014308751B2 (enExample) |
| CA (1) | CA2921805C (enExample) |
| HK (2) | HK1225742A1 (enExample) |
| WO (1) | WO2015027082A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| CU24446B1 (es) | 2013-03-13 | 2019-10-04 | Prothena Biosciences Ltd | Un anticuerpo monoclonal humanizado que se une a tau |
| WO2015027082A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| EP4005585B1 (en) | 2013-11-21 | 2024-03-27 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating right ventricular hypertrophy |
| JP6955443B2 (ja) | 2014-08-01 | 2021-10-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 肺動脈性肺高血圧症の処置に関する方法および組成物 |
| EP3922259A1 (en) | 2014-10-30 | 2021-12-15 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| PL3280727T3 (pl) * | 2015-04-06 | 2021-07-19 | Acceleron Pharma Inc. | Jednoramienne białka fuzyjne receptora typu I i typu II i ich zastosowania |
| AU2016244750B2 (en) | 2015-04-06 | 2021-02-18 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| KR101706462B1 (ko) * | 2015-07-09 | 2017-02-14 | 부산대학교 산학협력단 | Nag-1 억제제를 유효성분으로 포함하는 난소암 환자의 항암제 내성 억제용 약학조성물 |
| JP7320350B2 (ja) * | 2015-08-04 | 2023-08-03 | アクセルロン ファーマ インコーポレイテッド | 骨髄増殖性障害を処置するための方法 |
| ES3028883T3 (en) * | 2015-08-31 | 2025-06-20 | Nat Res Council Canada | Tgf-beta-receptor ectodomain fusion molecules and uses thereof |
| JP2019513224A (ja) * | 2016-03-04 | 2019-05-23 | エヌジーエム バイオファーマシューティカルス，インコー | 体重を調節するための組成物及び方法 |
| AU2017259039B2 (en) | 2016-05-02 | 2024-05-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EA201892417A1 (ru) | 2016-05-02 | 2019-05-31 | Протена Биосайенсис Лимитед | Антитела, распознающие тау |
| US10752679B2 (en) | 2016-05-02 | 2020-08-25 | Prothena Biosciences Limited | Tau immunotherapy |
| AU2017269496B2 (en) | 2016-05-24 | 2021-03-25 | Novo Nordisk A/S | MIC-1 compounds and use thereof |
| EP3519442A4 (en) | 2016-09-27 | 2020-06-17 | EpicentRx, Inc. | Immunomodulatory fusion proteins |
| AU2017338916B2 (en) | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
| JOP20190100A1 (ar) * | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
| SG11201906552WA (en) * | 2017-01-25 | 2019-08-27 | Tessa Therapeutics Pte Ltd | TGF-ß DECOY RECEPTOR |
| WO2018158727A1 (en) | 2017-03-02 | 2018-09-07 | National Research Council Of Canada | Tgf-β-receptor ectodomain fusion molecules and uses thereof |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| CN118406157A (zh) * | 2017-05-04 | 2024-07-30 | 阿塞勒隆制药公司 | TGF-β受体II型融合蛋白及其用途 |
| MY202480A (en) * | 2017-05-12 | 2024-04-30 | Shanghai hengrui pharmaceutical co ltd | Fusion protein containing tgf- receptor and medicinal uses thereof |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| JP2020536518A (ja) | 2017-09-27 | 2020-12-17 | エピセントアールエックス，インコーポレイテッド | 免疫調節融合タンパク質 |
| US20200377571A1 (en) | 2017-12-08 | 2020-12-03 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| AU2019216761B2 (en) * | 2018-02-09 | 2025-04-10 | Acceleron Pharma Inc. | Methods for treating heterotopic ossification |
| CN119431579A (zh) | 2018-03-09 | 2025-02-14 | 艾吉纳斯公司 | 抗cd73抗体及其使用方法 |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3765516A2 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| AU2019262143A1 (en) | 2018-05-03 | 2020-11-26 | Acceleron Pharma Inc. | Novel binders of TGFβ-superfamily ligands and uses thereof |
| WO2019246563A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| US11535669B2 (en) | 2018-07-09 | 2022-12-27 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| CN109097461B (zh) * | 2018-09-06 | 2021-07-30 | 北京中关村生命科学园生物医药科技孵化有限公司 | 一种心肌病相关基因检测试剂及其应用 |
| JP7465272B2 (ja) | 2018-09-27 | 2024-04-10 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体 |
| MX2021005018A (es) * | 2018-11-09 | 2021-06-15 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma. |
| GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
| CA3130754A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| WO2020172598A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| WO2020257823A2 (en) | 2019-06-21 | 2020-12-24 | Kite Pharma, Inc. | TGF-β RECEPTORS AND METHODS OF USE |
| JP2022540571A (ja) * | 2019-06-28 | 2022-09-16 | ゲンスン バイオファーマ、インコーポレーテッド | 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト |
| CN114616251B (zh) | 2019-10-21 | 2024-05-24 | 南京维立志博生物科技有限公司 | 靶向PD-1和TGFβ的重组蛋白 |
| JP7756638B2 (ja) | 2019-10-23 | 2025-10-20 | キュー バイオファーマ，インコーポレーテッド | ＴＧＦ－βポリペプチド |
| MX2022005491A (es) * | 2019-11-05 | 2022-07-27 | Acceleron Pharma Inc | Tratamientos contra esclerosis sistémica. |
| TWI772984B (zh) * | 2019-11-27 | 2022-08-01 | 大陸商上海岸邁生物科技有限公司 | TGFβ/PD-L1雙特異性結合蛋白 |
| EP4084823A4 (en) | 2020-01-03 | 2024-05-15 | Marengo Therapeutics, Inc. | ANTI-TCR ANTIBODY MOLECULES AND THEIR USES |
| EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| CA3180321A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| WO2021218883A1 (zh) * | 2020-04-28 | 2021-11-04 | 神州细胞工程有限公司 | 一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途 |
| CN113754777A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗PD-L1/TGF-β融合蛋白 |
| IL299764A (en) | 2020-07-10 | 2023-03-01 | Precigen Inc | Fusion constructs and methods for using them |
| US11028174B1 (en) | 2020-07-28 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Bifunctional molecules targeting PD-L1 and TGF-β |
| JP2023540248A (ja) | 2020-08-26 | 2023-09-22 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔｒｂｃ１またはｔｒｂｃ２を検出する方法 |
| EP4204096A4 (en) | 2020-08-26 | 2024-10-02 | Marengo Therapeutics, Inc. | ANTIBODY MOLECULES BINDING TO NKP30 AND USES THEREOF |
| EP4204450A4 (en) | 2020-08-26 | 2024-11-13 | Marengo Therapeutics, Inc. | MULTIFUNCTIONAL CALRETICULIN-BINDING MOLECULES AND RELATED USES |
| CN112215941B (zh) * | 2020-09-04 | 2021-06-25 | 北京科技大学 | 一种基于微分几何的主动脉扭曲的评估方法及系统 |
| WO2022068894A1 (zh) * | 2020-09-30 | 2022-04-07 | 上海齐鲁制药研究中心有限公司 | 同时靶向pd-l1和vegf的双功能分子及其医药用途 |
| WO2022105751A1 (zh) * | 2020-11-19 | 2022-05-27 | 信达生物制药(苏州)有限公司 | TGFβRII融合蛋白以及其用途 |
| US20240000891A1 (en) * | 2020-12-08 | 2024-01-04 | The Board Of Trustees Of The Leland Stanford Junior University | Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy |
| EP4351723A4 (en) * | 2021-06-11 | 2025-04-16 | Acceleron Pharma, Inc. | ACTRII PROTEINS AND THEIR USES |
| WO2023030408A1 (zh) * | 2021-09-02 | 2023-03-09 | 广东菲鹏制药股份有限公司 | TGFβRII突变体及其应用 |
| CA3243129A1 (en) | 2022-01-28 | 2023-08-03 | 35Pharma Inc | Activin receptor type iib variants and uses thereof |
| JP2024096518A (ja) * | 2023-01-03 | 2024-07-16 | エフビーデー バイオロジクス リミテッド | 操作されたｔｇｆｂｒｉｉバリアント及びその使用方法 |
| EP4653010A1 (en) | 2024-05-14 | 2025-11-26 | 35Pharma Inc. | Activin receptor type iib traps for use in improving body composition |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8529014D0 (en) | 1985-11-25 | 1986-01-02 | Biogen Nv | Enhanced secretion of heterologous proteins |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| IL98569A0 (en) | 1990-06-20 | 1992-07-15 | Bristol Myers Squibb Co | Pharmaceutical compositions containing tgf-b and antagonists thereof for modulating blood pressure |
| GB9106678D0 (en) | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| US6008011A (en) | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
| JP4124815B2 (ja) | 1991-10-31 | 2008-07-23 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | ＴＧＦ−β型受容体ｃＤＮＡおよびその用途 |
| US5543143A (en) | 1992-03-06 | 1996-08-06 | Corixa Corporation | Method for activating macrophages/monocytes |
| JPH08504763A (ja) * | 1992-10-29 | 1996-05-21 | セルトリックス ファーマシューティカルズ，インコーポレイテッド | 治療薬としてのＴＧＦ−βレセプターフラグメントの使用 |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| ATE355369T1 (de) | 1993-10-14 | 2006-03-15 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
| US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| US5866323A (en) | 1995-04-07 | 1999-02-02 | Case Western Reserve University | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors |
| NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| US6423501B2 (en) | 1996-12-13 | 2002-07-23 | Beth Israel Deaconess Medical Center | Calcium-independent negative regulation by CD81 of receptor signaling |
| AU737106B2 (en) | 1997-04-18 | 2001-08-09 | Biogen, Inc. | Type II TGF-beta receptor/immunoglobulin constant region fusion proteins |
| WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| ZA988461B (en) | 1997-09-18 | 1999-03-30 | Idec Pharma Corp | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2330939A1 (en) | 1998-06-16 | 1999-12-23 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| IL151369A0 (en) | 2000-03-09 | 2003-04-10 | Genzyme Corp | USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION |
| WO2001073128A1 (en) | 2000-03-24 | 2001-10-04 | Dzgenes, Llc | DIAGNOSTIC POLYMORPHISMS OF TGF-β-RII PROMOTER |
| US20030028905A1 (en) | 2001-07-31 | 2003-02-06 | Petra Knaus | Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms |
| JP4564261B2 (ja) | 2002-01-22 | 2010-10-20 | ジェンザイム、コーポレーション | 慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用 |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| WO2004056352A1 (en) | 2002-12-19 | 2004-07-08 | Scios, Inc. | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CA2535516A1 (en) | 2003-08-13 | 2005-03-03 | The Board Of Trustees Of The University Of Illinois | Silencing of tgf-beta receptor type ii expression by sirna |
| JP2007503393A (ja) | 2003-08-22 | 2007-02-22 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Ｃｏｐｄ及び肺高血圧の治療方法 |
| WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
| CA2568352C (en) * | 2004-06-04 | 2011-09-13 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat autoinflammatory disease |
| US7786261B2 (en) | 2004-09-02 | 2010-08-31 | National Research Council Of Canada | Coiled-coil fusion proteins comprising cell receptor domains |
| CN101084007A (zh) | 2004-09-22 | 2007-12-05 | 金齐姆公司 | TGF－β拮抗剂限制免疫抑制剂肾毒性的用途 |
| US7795389B2 (en) | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
| EP1809324A4 (en) | 2004-10-13 | 2009-02-25 | Univ Ohio State Res Found | METHOD FOR TREATING OR PREVENTING VIRAL LMPMPHOPROIBLE DISEASES |
| MX2007009545A (es) | 2005-02-08 | 2008-03-11 | Genzyme Corp | Anticuerpos para tgfbeta. |
| JP5342834B2 (ja) | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| ITMI20060181A1 (it) | 2006-02-03 | 2007-08-04 | Univ Padova | Modulatori del tgf-b e loro uso |
| US8454952B2 (en) | 2006-03-13 | 2013-06-04 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
| JP2009539842A (ja) | 2006-06-05 | 2009-11-19 | ノバルティス アクチエンゲゼルシャフト | 副甲状腺関連障害の処置におけるＴＧＦ−βアンタゴニストの使用 |
| DK2083863T3 (da) | 2006-10-03 | 2015-06-22 | Genzyme Corp | Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi |
| EP2140005B1 (en) | 2007-03-19 | 2013-12-11 | National Research Council of Canada | Fusion proteins comprising two tgf-beta binding domains |
| JP2010529859A (ja) * | 2007-06-15 | 2010-09-02 | ジェンザイム、コーポレーション | ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質 |
| ES2368876T3 (es) | 2007-08-22 | 2011-11-23 | Irm Llc | Derivados de 2-heteroarilaminopirimidina como inhibidores de cinasa. |
| WO2009092087A2 (en) | 2008-01-18 | 2009-07-23 | The Brigham And Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human th17 cells |
| MX2010011998A (es) * | 2008-05-02 | 2011-04-11 | Acceleron Pharma Inc | Metodos y composiciones de pericitos para regular la angiogenesis y composicion de pericapilar. |
| WO2009143309A2 (en) | 2008-05-21 | 2009-11-26 | Trustees Of Dartmouth College | Female reproductive tract and anal prophylaxes |
| WO2009152610A1 (en) | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
| US20100015144A1 (en) * | 2008-06-26 | 2010-01-21 | Acceleron Pharma Inc. | Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
| KR20110044992A (ko) * | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| CA2737271C (en) * | 2008-09-17 | 2020-06-23 | National Research Council Of Canada | Hetero-multivalent binding agents for members of the tgf.beta. superfamily |
| WO2010048273A2 (en) | 2008-10-21 | 2010-04-29 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
| US8138142B2 (en) | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
| JP5755635B2 (ja) * | 2009-03-30 | 2015-07-29 | アクセルロン ファーマ， インコーポレイテッド | Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用 |
| US20120114640A1 (en) | 2009-05-08 | 2012-05-10 | Kulkarni Ashok B | MODULATION OF THE TGF- ß AND PI3K/AKT PATHWAYS IN THE DIAGNOSIS AND TREATMENT OF SQUAMOUS CELL CARCINOMA |
| US20110172296A1 (en) | 2010-01-12 | 2011-07-14 | Bennett C Frank | Modulation of transforming growth factor-beta 1 expression |
| ES2638521T5 (es) * | 2010-03-05 | 2021-03-02 | Univ Johns Hopkins | Composiciones y métodos para anticuerpos y proteínas de fusión inmunomoduladores dirigidos contra dianas |
| CN101852804B (zh) * | 2010-03-29 | 2013-06-12 | 中国医学科学院病原生物学研究所 | Gdf15蛋白的抗体的新用途 |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| EP2611831B1 (en) | 2010-09-01 | 2018-12-12 | Genzyme Corporation | Treatment of myocardial infarction using tgf-beta antagonists |
| US20130287688A1 (en) | 2010-11-18 | 2013-10-31 | Xtuit Pharmaceuticals, Inc. | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| US8800906B2 (en) | 2010-12-27 | 2014-08-12 | The Board Of Trustees Of The Leland Stanford Junior University | Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain |
| ES2627299T3 (es) | 2011-01-06 | 2017-07-27 | Glaxo Group Limited | Ligandos que se unen al receptor II del TGF-beta |
| EP3549952A1 (en) | 2011-04-20 | 2019-10-09 | Acceleron Pharma Inc. | Endoglin polypeptides and uses thereof |
| CN102850458B (zh) * | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| WO2013012648A1 (en) * | 2011-07-15 | 2013-01-24 | Emory University | Gdf15 in diagnostic and therapeutic applications |
| WO2013019805A1 (en) | 2011-08-01 | 2013-02-07 | Tufts Medical Center, Inc. | Treatment of heart failure and related conditions |
| WO2013059879A1 (en) | 2011-10-26 | 2013-05-02 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
| CN108503711A (zh) | 2012-04-30 | 2018-09-07 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
| HK1208361A1 (en) | 2012-05-16 | 2016-03-04 | Aadigen, Llc | Multi-target modulation for treating fibrosis and inflammatory conditions |
| SI2971048T1 (sl) | 2013-03-11 | 2019-03-29 | Genzyme Corporation | Sintetična protitelesa proti-TGF-BETA in delci, ki vežejo antigen |
| DK2970512T3 (en) | 2013-03-12 | 2019-01-14 | Biocon Ltd | IMMUNO MODULATOR FUSION PROTEINS AND PROCEDURES FOR PRODUCING THEREOF |
| CN105452287A (zh) | 2013-04-17 | 2016-03-30 | 贝勒医学院 | 免疫抑制性TGF-β信号转换器 |
| WO2015027082A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| EP4005585B1 (en) | 2013-11-21 | 2024-03-27 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating right ventricular hypertrophy |
| DK3105246T3 (da) | 2014-02-10 | 2021-06-14 | Merck Patent Gmbh | Målrettet TGF-beta-inhibering |
| WO2015179227A1 (en) | 2014-05-18 | 2015-11-26 | Children's Medical Center Corporation | Methods and compositions relating to exosomes |
| KR20170018829A (ko) | 2014-06-13 | 2017-02-20 | 노파르티스 아게 | Gdf-15를 감소시키기 위한 세렐락신의 용도 |
| JP6955443B2 (ja) | 2014-08-01 | 2021-10-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 肺動脈性肺高血圧症の処置に関する方法および組成物 |
| AU2016244750B2 (en) | 2015-04-06 | 2021-02-18 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| JP7320350B2 (ja) | 2015-08-04 | 2023-08-03 | アクセルロン ファーマ インコーポレイテッド | 骨髄増殖性障害を処置するための方法 |
| ES3028883T3 (en) | 2015-08-31 | 2025-06-20 | Nat Res Council Canada | Tgf-beta-receptor ectodomain fusion molecules and uses thereof |
| WO2017134592A1 (en) | 2016-02-03 | 2017-08-10 | Biocon Limited | Anti-cd20/immunomodulatory fusion proteins and methods for making same |
| KR20190039200A (ko) | 2016-08-12 | 2019-04-10 | 메르크 파텐트 게엠베하 | 암에 대한 조합 요법 |
| EP3519442A4 (en) | 2016-09-27 | 2020-06-17 | EpicentRx, Inc. | Immunomodulatory fusion proteins |
| SG11201906157YA (en) | 2017-01-07 | 2019-08-27 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
| WO2018158727A1 (en) | 2017-03-02 | 2018-09-07 | National Research Council Of Canada | Tgf-β-receptor ectodomain fusion molecules and uses thereof |
| CN118406157A (zh) | 2017-05-04 | 2024-07-30 | 阿塞勒隆制药公司 | TGF-β受体II型融合蛋白及其用途 |
| AU2019216761B2 (en) | 2018-02-09 | 2025-04-10 | Acceleron Pharma Inc. | Methods for treating heterotopic ossification |
-
2014
- 2014-08-21 WO PCT/US2014/052130 patent/WO2015027082A1/en not_active Ceased
- 2014-08-21 AU AU2014308751A patent/AU2014308751B2/en active Active
- 2014-08-21 HK HK16113935.3A patent/HK1225742A1/zh unknown
- 2014-08-21 CN CN202310399163.0A patent/CN116655801A/zh active Pending
- 2014-08-21 US US14/465,182 patent/US20150056199A1/en not_active Abandoned
- 2014-08-21 HK HK16113925.5A patent/HK1225740A1/zh unknown
- 2014-08-21 EP EP20153745.3A patent/EP3705498A1/en active Pending
- 2014-08-21 CN CN201480057870.0A patent/CN105658672A/zh active Pending
- 2014-08-21 JP JP2016536456A patent/JP2016528295A/ja not_active Withdrawn
- 2014-08-21 EP EP14837885.4A patent/EP3036262A4/en not_active Withdrawn
- 2014-08-21 CA CA2921805A patent/CA2921805C/en active Active
-
2016
- 2016-02-16 US US15/044,883 patent/US9809637B2/en active Active
-
2017
- 2017-09-25 US US15/714,015 patent/US10316076B2/en active Active
-
2019
- 2019-04-24 US US16/393,277 patent/US10981973B2/en active Active
- 2019-08-19 JP JP2019149750A patent/JP2019194270A/ja not_active Withdrawn
-
2020
- 2020-01-30 US US16/777,546 patent/US11008377B2/en active Active
- 2020-05-28 AU AU2020203514A patent/AU2020203514B2/en active Active
-
2021
- 2021-04-13 US US17/229,132 patent/US20210230252A1/en not_active Abandoned
- 2021-05-10 JP JP2021079785A patent/JP2021112212A/ja active Pending
-
2023
- 2023-11-24 JP JP2023199004A patent/JP2024015040A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528295A5 (enExample) | ||
| JP7685737B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| US11919931B2 (en) | Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3) | |
| CN110573532B (zh) | TGF-β 受体胞外域融合分子及其用途 | |
| KR102668200B1 (ko) | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 | |
| US9493530B2 (en) | FGF21 mutants comprising a mutation at position 98, 171 and/or 180 | |
| EP3144320B1 (en) | Fc fusion proteins comprising novel linkers or arrangements | |
| Baldwin | Comparison of transferrin sequences from different species | |
| EP2585098B1 (en) | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders | |
| JP2008500373A5 (enExample) | ||
| JP2006512894A5 (enExample) | ||
| CN106687478A (zh) | 新的抗人Tie‑2抗体 | |
| EP3355908A1 (en) | Treatment of bile acid disorders | |
| US10618949B2 (en) | Method and compositions for producing disulfide-linked trimeric TNF family of cytokines and their use | |
| WO2020093789A1 (zh) | 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用 | |
| ITFI20090006A1 (it) | Processo per la produzione di proteine di fusione polivalenti e polispecifiche utilizzando come struttura portante l'uteroglobina e prodotti cosi' ottenuti. | |
| EP2597102A1 (en) | A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17 | |
| ES2956439T3 (es) | Proteína de fusión | |
| US11377490B2 (en) | Method for treating cancer using disulfide-linked trimeric 4-1BBL | |
| US11026996B2 (en) | Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling | |
| JPWO2019213446A5 (enExample) | ||
| JPWO2019213442A5 (enExample) | ||
| HK40029335A (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| HK40086042A (zh) | 双功能蛋白质和包含其的药物组合物 | |
| HK1234078B (zh) | 新的抗人tie-2抗体 |